We have located links that may give you full text access.
Variances in the mRNA expression profile of TGF-β1-3 isoforms and its TGF-βRI-III receptors during cyclosporin a treatment of psoriatic patients.
Postȩpy Dermatologii i Alergologii 2018 October
Introduction: Psoriasis is a chronic, immunologic, multi-factor inflammatory skin disease, strongly associated with a higher level of a number of cytokines, such as isoforms of transforming growth factor β (TGF-β1-3) and its receptors (TGF-βRI-III). One of the most popular and important drugs used to treat this disease is cyclosporin A (CsA).
Aim: The aim of this study was to investigate the expression of genes encoding the transforming growth factor (TGF)-β isoforms and receptors of the cytokine TGF-βRs in psoriatic patients during an 84-day long observation of the effects of cyclosporin A therapy. It made an attempt to determine the usefulness of testing mRNA expression of TGF- β 1 - 3 and its receptors TGF- β RI-III as the supplementary molecular markers of lost sensitivity to the medicine.
Material and methods: The study group consisted of 32 patients with psoriasis (20 men and 12 women) treated with cyclosporin A. The changes in expression patterns of TGF- β 1-3 and TGF- β RI-III were performed by real-time quantitative reverse transcription PCR (RTqPCR).
Results: The expression of TGF- β 1-3 and TGF- β RI-III were detected in the whole period of therapy with CsA. Changes in transcriptional activities of TGF- β 1-3 and TGF- β RI-III during pharmacotherapy were observed. Differences in the expression of these genes were found before and after 42 and 84 days of using CsA.
Conclusions: The changes in expression profiles of TGF- β 1-3 and TGF- β RI-III during CsA therapy can be a useful molecular marker of lost sensitivity to the medicine.
Aim: The aim of this study was to investigate the expression of genes encoding the transforming growth factor (TGF)-β isoforms and receptors of the cytokine TGF-βRs in psoriatic patients during an 84-day long observation of the effects of cyclosporin A therapy. It made an attempt to determine the usefulness of testing mRNA expression of TGF- β 1 - 3 and its receptors TGF- β RI-III as the supplementary molecular markers of lost sensitivity to the medicine.
Material and methods: The study group consisted of 32 patients with psoriasis (20 men and 12 women) treated with cyclosporin A. The changes in expression patterns of TGF- β 1-3 and TGF- β RI-III were performed by real-time quantitative reverse transcription PCR (RTqPCR).
Results: The expression of TGF- β 1-3 and TGF- β RI-III were detected in the whole period of therapy with CsA. Changes in transcriptional activities of TGF- β 1-3 and TGF- β RI-III during pharmacotherapy were observed. Differences in the expression of these genes were found before and after 42 and 84 days of using CsA.
Conclusions: The changes in expression profiles of TGF- β 1-3 and TGF- β RI-III during CsA therapy can be a useful molecular marker of lost sensitivity to the medicine.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app